Specifically, Pirfenidone, a TGF-β inhibitor and scavenger of reactive oxygen species, and Nintedanib, a tyrosine kinase inhibitor, were approved by the FDA for treatment of idiopathic pulmonary fibrosis [78,79,80]. Here, TGFB1 is linked to idiopathic pulmonary fibrosis.